Search

Author/Creator Andreadis, C.

1. CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS. (12th June 2019)

Authors:
Bachanova, V.; Westin, J.; Tam, C.; Borchmann, P.; Jaeger, U.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Bishop, M.; Andreadis, C.; Foley, S.R.; Fleury, I.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Maziarz, R.; Van Besien, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
308
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. EFFICACY AND SAFETY OF TISAGENLECLEUCEL (TISA‐CEL) IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): PRIMARY ANALYSIS OF THE PHASE 2 ELARA TRIAL. (17th June 2021)

Authors:
Schuster, S. J.; Dickinson, M.; Dreyling, M.; Martinez‐Lopez, J.; Kolstad, A.; Butler, J.; Ghosh, M.; Popplewell, L.; Chavez, J. C.; Bachy, E.; Kato, K.; Harigae, H.; Kersten, M. José; Andreadis, C.; Riedell, P. A.; Abdelhady, A.; Zia, A.; Morisse, M. C.; Fowler, N. H.; Thieblemont, C.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. (June 2017)

Authors:
Schuster, S.J.; Bishop, M.R.; Tam, C.; Waller, E.K.; Borchmann, P.; Mcguirk, J.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Holte, H.; Anak, O.; Pacaud, L.; Awasthi, R.; Tai, F.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
27
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. (12th June 2019)

Authors:
Jaeger, U.; Tam, C.; Borchmann, P.; McGuirk, J.; Holte, H.; Waller, E.; Jaglowski, S.; Andreadis, C.; Foley, S.R.; Fleury, I.; Westin, J.; Teshima, T.; Mielke, S.; Salles, G.; Ho, P.J.; Izutsu, K.; Schuster, S.; Bachanova, V.; Maziarz, R.; Van Besien, K.
Journal:
Hematological oncology
Issue:
Volume 37(2019)Supplement 2
Page Start:
505
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY. (23rd June 2022)

Authors:
Herrera, A. F.; Lavie, D.; Johnson, N. A.; Avigdor, A.; Borchmann, P.; Andreadis, C.; Bazargan, A.; Gregory, G.; Keane, C.; Inna, T.; Vucinic, V.; Zinzani, P. L.; Zhang, H.; Pillai, P.; Marinello, P.; Timmerman, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
977
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM. (23rd June 2022)

Authors:
Wang, Y.; Jain, P.; Locke, F.; Maurer, M.; Frank, M.; Munoz, J.; Dahiya, S.; Beitinjaneh, A.; Jacobs, M.; Mcguirk, J.; Vose, J.; Goy, A.; Andreadis, C.; Hill, B.; Dorritie, K.; Oluwole, O.; Deol, A.; Shah, B.; Paludo, J.; Wang, T.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1042
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. PATIENT‐REPORTED QUALITY OF LIFE (QOL) FOLLOWING TISAGENLECLEUCEL (TISA‐CEL) INFUSION IN ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL). (17th June 2021)

Authors:
Fowler, N. H.; Dickinson, M.; Martinez‐Lopez, J.; Kolstad, A.; Schuster, S. J.; Dreyling, M.; Ghosh, M.; Harigae, H.; Kersten, M. José; Bachy, E.; Popplewell, L.; Chavez, J. C.; Ho, P. J.; Butler, J.; Kato, K.; von Tresckow, B.; Ferreri, A. J. M.; Simón, J. A. P.; Patten, P. E. M.; Andreadis, C.
Journal:
Hematological oncology
Issue:
Volume 39(2021)Supplement 2
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. PO-45: Cancer-associated thrombosis (CAT) in gynecological cancers: data from ACT4CAT study. Issue 213 (May 2022)

Authors:
Tsoukalas, N.; Christopoulou, A.; Timotheadou, E.; Athanasiadis, I.; Koumarianou, A.; Peroukidis, S.; Samelis, G.; Psyrri, A.; Kapodistrias, N.; Nikolakopoulos, A.; Andreadis, C.; Ardavanis, A.; Samantas, E.; Papandreou, C.; Mavroudis, D.; Bokas, A.; Barbounis, V.; Kentepozidis, N.; Athanasiadis,...
Journal:
Thrombosis research
Issue:
Issue 213(2022)Supplement 2
Page Start:
S32
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Rationale and design of the real-world Hellenic disease management patterns with everolimus for women with hormone-receptor-positive, human epidermal growth factor ReceptOR-2 negative advanced breast cancer (The MIRROR) study. (March 2017)

Authors:
Karanikiotis, C.; Kesisis, G.; Xanthakis, I.; Alexopoulos, A.; Barbounis, V.; Panopoulos, C.; Andreadis, C.; Papadimitriou, C.
Journal:
Breast
Issue:
Volume 32(2017)Supplement 1
Page Start:
S69
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗